PATINA: A randomized, open label, phase III trial to evaluate the efficacy and safety of palbociclib Anti-HER2 therapy endocrine therapy (ET) vs. anti-HER2 therapy ET after induction treatment for hormone receptor positive (HR )/HER2-positive metastatic breast cancer (MBC)

S Loibl; O Metzger; SJ Mandrekar; C Mundhenke; S Seiler; P Valagussa; A DeMichele; E Lim; D Tripathy; EP Winer; C Huang; L Carey; P Francis; KD Miller; MP Goetz; A Prat; S Loi; I Krop; L Gianni; EM Ciruelos

Conference Proceedings

PATINA: A randomized, open label, phase III trial to evaluate the efficacy and safety of palbociclib Anti-HER2 therapy endocrine therapy (ET) vs. anti-HER2 therapy ET after induction treatment for hormone receptor positive (HR )/HER2-positive metastatic breast cancer (MBC)

S Loibl, O Metzger, SJ Mandrekar, C Mundhenke, S Seiler, P Valagussa, A DeMichele, E Lim, D Tripathy, EP Winer, C Huang, L Carey, P Francis, KD Miller, MP Goetz, A Prat, S Loi, I Krop, L Gianni, EM Ciruelos

Annals of oncology : official journal of the European Society for Medical Oncology | OXFORD UNIV PRESS | Published : 2018

DOI: 10.1093/annonc/mdy272.357

University of Melbourne Researchers

Prudence A. Francis Author

Shom Goel Author

Grants

Funding Acknowledgements

The study is sponsored by Alliance Foundation Trials (AFT) and financially supported by Pfizer.

Citation metrics

2Scopus

3Web of Science

28Dimensions

Keywords

Life Sciences & Biomedicine

Oncology

Cancer

Clinical Trials and Supportive Activities

32 Biomedical and Clinical Sciences

3211 Oncology and Carcinogenesis